CLBS - CLBS STOCK NEWS

Caladrius Biosciences announces the resignation of Chief Medical Officer Dr. Douglas Losordo, effective immediately. He will be succeeded by Robert Honigberg, M.D. as interim CMO to ensure continuity in clinical and regulatory efforts. Honigberg, an experienced professional with a strong background in the cardiovascular field, is expected to support the company in reaching crucial clinical milestones. Caladrius focuses on developing cellular therapies to reverse disease, with ongoing initiatives including treatments for ischemic diseases and COVID-19 related conditions.

Caladrius Biosciences (Nasdaq: CLBS) announced its participation in the American Heart Association's (AHA) Scientific Sessions from November 13-17, 2020, with a presentation focused on COVID-19. The session will feature an abstract titled Autologous CD34+ Cells (CLBS119) for Repair of Covid-19 Induced Microvascular Lung Damage: Rationale and Study Design, presented by Chief Medical Officer Douglas W. Losordo. This highlights the company's commitment to cellular therapies that reverse diseases and address the pulmonary damage caused by the virus.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) reported its corporate update and financial results for Q3 2020, revealing a net loss of $5.3 million. Despite challenges from COVID-19, the company extended its cash runway to the end of 2021, having raised approximately $30 million year-to-date. Key developments include the initiation of the CLBS119 study for COVID-19 lung damage, progress in Japan with HONEDRA®, and plans for a Phase 2b trial of CLBS16. R&D expenses remained steady at $3.0 million, while cash and equivalents stand at $40.3 million as of September 30, 2020.

Caladrius Biosciences (Nasdaq: CLBS) announced its participation in three virtual investor conferences in November 2020, showcasing its commitment to cellular therapies aimed at reversing disease. The conferences include the LSX Virtual Inv€$tival Showcase from November 11-16, the Jefferies Virtual London Healthcare Conference from November 17-19, and the A.G.P. Virtual Healthcare Symposium on November 19. Management will hold one-on-one meetings at these events to discuss their innovative therapies, including HONEDRA® and CLBS14. For inquiries, contact investor relations directly.

Caladrius Biosciences (CLBS) has appointed Anne Whitaker to its Board of Directors. With 28 years in the life sciences sector, Whitaker has held senior roles in major pharmaceutical companies, demonstrating expertise in commercializing therapies and leading teams. Her previous roles include CEO of Aerami Therapeutics and President/CEO of Synta Pharmaceuticals. The Board welcomes her insights during a pivotal time for Caladrius as it advances late-stage clinical programs, including therapies for ischemic diseases.

Caladrius Biosciences (Nasdaq: CLBS) will report its Q3 2020 financial results on November 5, 2020, at 4:30 p.m. ET. The company, focused on cellular therapies for disease reversal, aims to enhance investor engagement with a live conference call and webcast. Participants can join via U.S. or international dial-in options, and a recording will be available shortly after. Noteworthy products include HONEDRA® for critical limb ischemia, CLBS14 for disabling angina, CLBS16 for coronary microvascular dysfunction, and CLBS119 targeting COVID-19 related lung damage.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) announced that Chief Medical Officer Douglas W. Losordo will participate in the 8th annual Chief Medical Officer Summit 360° on October 26-27, 2020. Losordo's breakout session titled "Tracking Personalized Medications in Gene and Cell Therapy" is scheduled for October 26 at 3:00 p.m. The company focuses on cellular therapies aimed at reversing diseases, with product candidates like CLBS119 for COVID-19 lung damage and HONEDRA® for critical limb ischemia. For more details, visit www.caladrius.com.

Caladrius Biosciences (Nasdaq: CLBS) has initiated a clinical trial for CLBS119, targeting COVID-19-induced lung damage. The study, taking place at NYU Langone Health, aims to evaluate the safety and efficacy of a single administration of CLBS119, a therapy using CD34+ cells. This proof-of-concept trial will include 12 patients suffering from hypoxia following SARS-CoV-2 infection. The Chief Medical Officer emphasized the unmet medical need for treatments that can repair long-term lung damage caused by COVID-19.

Caladrius Biosciences (Nasdaq: CLBS) announced that its Chief Medical Officer, Douglas W. Losordo, will present at the Alliance for Regenerative Medicine's Cell and Gene Meeting on the Mesa from October 12-16, 2020. This virtual conference is a key event for leaders in cell and gene therapy, addressing commercialization challenges and featuring on-demand presentations and live-stream panels. Caladrius is focused on cellular therapies, including CLBS119 for severe COVID-19 lung damage and therapies for ischemic diseases, such as HONEDRA® and CLBS16.